Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. Read more to see 2 ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

We recently compiled a list of the 13 Cheap High Dividend Stocks To Invest In Now. In this article, we are going to take a ...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc.

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

However, analysts project potential upside of 92% in 2025, according to the Street-high estimate.  Investors should also note that Merck pays a dividend yielding 3.71%, more than twice the healthcare ...

Now that Merck stock has been beaten down, it offers a higher yield than we usually see from the well-established ...

Merck & Co Inc (MRK) reports robust sales growth driven by KEYTRUDA and WINREVAIR, while navigating GARDASIL demand issues in China. Earnings are painting a mixed picture within the pharmaceutical ...

Merck’s new drugs – Winrevair and Capvaxive – have been gaining momentum. On the flip side, Gardasil sales fell 17% to $1.55 billion, due to a continued decline in China. Januvia and Janumet ...

Merck reported adjusted EPS of $1.72 ... Across the commercial portfolio, the analyst remains bullish on Winrevair's potential. Analyst Shibutani writes that the company is well-equipped to ...